D. Pruneau

发表

Control of Conformational Equilibria in the Human B2 Bradykinin Receptor

B. Maigret, E. Richard, J. Marie, 2001, The Journal of Biological Chemistry.

Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI.

B. Maigret, C. Koch, J. Marie, 1999, Molecular pharmacology.

Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia

D. Lumenta, S. Zausinger, A. Baethmann, 2006, Brain Research.

Optogenetic therapy: High spatiotemporal resolution and pattern recognition compatible with vision restoration in non-human primates

O. Marre, J. Sahel, F. Arcizet, 2020, bioRxiv.

Pharmacological characterization of the bradykinin B2 receptor: inter‐species variability and dissociation between binding and functional responses

D. Pruneau, J. Paquet, J. Luccarini, 1999, British journal of pharmacology.

Therapeutic window of bradykinin B2 receptor inhibition after focal cerebral ischemia in rats

N. Plesnila, D. Lumenta, S. Zausinger, 2006, Neurochemistry International.

Activation of liver X receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells

E. Disse, R. Rabasa-Lhoret, M. Laville, 2006, Diabetologia.

Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier.

F. Hellal, M. Plotkine, D. Rodi, 2006, Journal of neurotrauma.

Therapeutical efficacy of a novel non-peptide bradykinin B2 receptor antagonist on brain edema formation and ischemic tissue damage in focal cerebral ischemia.

N. Plesnila, D. Lumenta, S. Zausinger, 2003, Acta neurochirurgica. Supplement.

LF 16‐0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia

B. Palmier, M. Plotkine, I. Margaill, 2003, British journal of pharmacology.

Role of bradykinin B2 receptors in the formation of vasogenic brain edema in rats.

N. Plesnila, M. Stoffel, A. Baethmann, 2001, Journal of neurotrauma.

ω‐Conotoxin GVIA, the N‐Type Calcium Channel Inhibitor, is Sympatholytic but not Vagolytic: Consequences for Hemodynamics and Autonomic Reflexes in Conscious Rabbits

J. Angus, D. Pruneau, 1990, Journal of cardiovascular pharmacology.

Bradykinin B2 receptor antagonism with LF 18-1505T reduces brain edema and improves neurological outcome after closed head trauma in rats.

A. Artru, M. Benifla, Y. Shapira, 2006, The Journal of trauma.

LF 16-0687 Ms, a new bradykinin B2 receptor antagonist, improves neurologic outcome but not brain tissue prostaglandin E2 release in a rat model of closed head trauma combined with ethanol intoxication.

A. Artru, J. Kaplanski, Y. Shapira, 2003, The Journal of trauma.

Decreased susceptibility to arrhythmias in hypertrophied hearts of physically trained rats

J. Salzmann, R. Rouet, D. Pruneau, 1992, Basic Research in Cardiology.

[Arterial hypertension, myocardial hypertrophy and disorders of cardiac rhythm induced by ligation of the left coronary artery in the rat].

L. Rochette, D. Pruneau, P. Bélichard, 1987, Archives des maladies du coeur et des vaisseaux.

Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster.

D. Pruneau, P. Bélichard, A. Zhiri, 1993, Biochimica et biophysica acta.

LF 16.0335, a novel potent and selective nonpeptide antagonist of the human bradykinin B2 receptor

D. Pruneau, J. Paquet, J. Luccarini, 1998, British journal of pharmacology.

Synthesis and in Vivo pharmacological profile of dimeric HOE 140 bradykinin antagonists

Jean Martínez, M. Amblard, D. Pruneau, 2002 .

Synthesis and pharmacological evaluation of dimer derivatives of the bradykinin receptor antagonist HOE-140.

M. Amblard, D. Pruneau, J. Paquet, 2009, The journal of peptide research : official journal of the American Peptide Society.

Pharmacological evidence for a single bradykinin B2 receptor in the guinea‐pig

D. Pruneau, J. Paquet, J. Luccarini, 1995, British journal of pharmacology.

Identification of a Key Region of Kinin B1 Receptor for High Affinity Binding of Peptide Antagonists*

J. Bonnafous, D. Pruneau, J. Paquet, 2000, The Journal of Biological Chemistry.

Interleukin 8 (IL-8) induces the expression of kinin B1 receptor in human lung fibroblasts.

D. Bachvarov, F. Marceau, J. Larrivée, 1998, Biochemical and biophysical research communications.

Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization

D. Pruneau, J. Paquet, B. Loillier, 1997, British journal of pharmacology.

Characterisation of bradykinin receptors from juvenile pig coronary artery.

D. Pruneau, J. Paquet, J. Luccarini, 1996, European journal of pharmacology.

Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist.

D. Pruneau, J. Paquet, J. Luccarini, 1999, Immunopharmacology.

Cardiovascular properties of LF 2.0254, a new potent vasoselective calcium channel blocker with a slow onset of action

D. Pruneau, F. Roy, NL Brown, 1990, Fundamental & clinical pharmacology.

Effects of LF 16-0687 Ms, a bradykinin B2 receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia

N. Plesnila, D. Lumenta, S. Zausinger, 2002, Brain Research.

In vitro and in vivo effects of the new nonpeptide bradykinin B2 receptor antagonist, LF 16‐0335C, on guinea‐pig and rat kinin receptors

D. Pruneau, J. Paquet, J. Luccarini, 1999, Fundamental & clinical pharmacology.

LF16-0687 a novel non-peptide bradykinin B2 receptor antagonist reduces vasogenic brain edema from a focal lesion in rats.

N. Plesnila, M. Stoffel, A. Baethmann, 2000, Acta neurochirurgica. Supplement.

Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury.

B. Palmier, F. Hellal, M. Plotkine, 2003, Journal of neurotrauma.

Trifluoperazine antagonizes postsynaptic α1- but not α2-adrenoceptor-mediated pressor responses in the rat

Y. Mainguy, D. Pruneau, F. Roy, 1984 .

Evidence for pH as an important parameter to control when studying the contractility of isolated rabbit cerebral arteries

J. Elghozi, D. Pruneau, V. Deckert, 1994, Fundamental & clinical pharmacology.

Influence of spontaneous hypertension and cardiac hypertrophy on the severity of ischemic arrhythmias in the rat

L. Rochette, D. Pruneau, P. Bélichard, 1988, Basic Research in Cardiology.

The kinin B1 receptor antagonist des‐Arg9‐[Leu8]bradykinin: an antagonist of the angiotensin AT1 receptor which also binds to the AT2 receptor

J. Bonnafous, D. Pruneau, J. Luccarini, 1995, British journal of pharmacology.

Induction of kinin B1 receptor‐dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery

D. Pruneau, J. Luccarini, C. Robert, 1994, British journal of pharmacology.

Induction of kinin B 1 receptor-dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery '

D. Pruneau, J. Luccarini, C. Robert, 2022 .

Inflammatory hyperalgesia induced by zymosan in the plantar tissue of the rat: effect of kinin receptor antagonists.

M. Landry, D. Bachvarov, F. Marceau, 2000, Immunopharmacology.

Endothelium-dependent control of vascular tone in the rabbit kidney after ischemia and reperfusion.

D. Pruneau, P. Bélichard, 1993, European journal of pharmacology.

The importance of kinin antagonist treatment timing in closed head trauma.

A. Artru, Y. Shapira, D. Pruneau, 2001, The Journal of trauma.

Effect of LF 16-0687MS, a new nonpeptide bradykinin B2 receptor antagonist, in a rat model of closed head trauma.

A. Artru, Y. Shapira, D. Pruneau, 1999, Journal of neurotrauma.

From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.

D. Pruneau, J. Paquet, J. Luccarini, 2012, Journal of medicinal chemistry.

Antinociceptive Pharmacology of N-[[4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, Fumarate (LF22-0542), a Novel Nonpeptidic Bradykinin B1 Receptor Antagonist

T. Vanderah, J. Junien, F. Porreca, 2006, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological and molecular evidence for kinin B1 receptor expression in urinary bladder of cyclophosphamide‐treated rats

D. Pruneau, J. Paquet, J. Luccarini, 1999, British journal of pharmacology.

Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.

M. Amblard, D. Pruneau, J. Paquet, 1999, Journal of medicinal chemistry.

Synthesis and biological evaluation of bradykinin B1/B2 and selective B1 receptor antagonists

Jean Martínez, M. Amblard, D. Pruneau, 2000 .

A rational approach to the design and synthesis of a new bradykinin B(1) receptor antagonist.

M. Amblard, A. Aumelas, G. Subra, 2000, Journal of medicinal chemistry.

Synthesis and characterization of bradykinin B(2) receptor agonists containing constrained dipeptide mimics.

M. Amblard, M. Calmès, D. Pruneau, 1999, Journal of medicinal chemistry.

Cloning and characterization of guinea pig interleukin-8 receptor.

J. Catusse, D. Pruneau, J. Paquet, 2003, Biochemical pharmacology.

Reduction of intimal hyperplasia by naroparcil, a 4-methylumbelliferyl beta-D-xyloside analogue, after arterial injury in the hypercholesterolemic rabbit.

M. Ziol, P. Bruneval, D. Pruneau, 1995, Circulation research.

Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates

O. Marre, J. Sahel, F. Arcizet, 2021, Communications Biology.

A stimulation platform for optogenetic and bionic vision restoration

Ryad Benosman, Christoph Posch, Francesco Galluppi, 2017, 2017 IEEE International Symposium on Circuits and Systems (ISCAS).

Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2.

J. Catusse, D. Pruneau, J. Paquet, 2003, Biochemical pharmacology.

Haemodynamic and humoral effects of omega-conotoxin GVIA in normotensive and spontaneously hypertensive rats.

D. Pruneau, P. Bélichard, 1992, European journal of pharmacology.

ω‐Conotoxin GVIA is a potent inhibitor of sympathetic neurogenic responses in rat small mesenteric arteries

J. Angus, D. Pruneau, 1990, British journal of pharmacology.

Comparison of contractile responses to 5‐hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2‐receptor agonist, U46619

J. Angus, T. Cocks, D. Pruneau, 1993, British journal of pharmacology.

Release of Bradykinin and Expression of Kinin B2 Receptors in the Brain: Role for Cell Death and Brain Edema Formation After Focal Cerebral Ischemia in Mice

N. Plesnila, M. Gröger, J. Relton, 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

High-performance liquid chromatographic procedure for measuring ATP and ADP levels in tissue microbiopsy: application to rat wound healing proliferative tissue.

M. Pascal, D. Pruneau, E. Wülfert, 1982, Analytical biochemistry.

Pharmacological and functional characterization of the guinea‐pig B2 bradykinin receptor stably expressed in CHO‐K1 cell line

D. Pruneau, J. Paquet, C. Robert, 2002, British journal of pharmacology.

LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats.

A. Artru, Y. Shapira, D. Pruneau, 2002, Journal of neurotrauma.

LF 16-0687 Ms, a new bradykinin B2 receptor antagonist, decreases ex vivo brain tissue prostaglandin E2 synthesis after closed head trauma in rats.

A. Artru, Y. Shapira, D. Pruneau, 2003, Resuscitation.

903 LF 16.0687, a new nonpeptide bradykinin B2 receptor antagonist, reduces cerebral edema in a rat model of closed head trauma

D. Talmor, Y. Shapira, D. Pruneau, 1999 .

Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy.

J. Sahel, D. Pruneau, P. Bélichard, 2010, Current opinion in investigational drugs.

The arterial wall: a new pharmacological and therapeutic target *

J. Elghozi, B. Dupuis, J. Elghozi, 1995, Fundamental & clinical pharmacology.

Apparent vascular to cardiac sympatholytic selectivity of ω-conotoxin GVIA in the pithed rat

J. Angus, D. Pruneau, 1990 .

Induction of bradykinin B1 receptor-mediated relaxation in the isolated rabbit carotid artery.

D. Pruneau, P. Bélichard, 1993, European journal of pharmacology.

Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists.

M. Amblard, D. Pruneau, J. Paquet, 2000, Journal of medicinal chemistry.

Mediation by 5‐HT1D receptors of 5‐hydroxytryptamine‐induced contractions of rabbit middle and posterior cerebral arteries

J. Elghozi, D. Pruneau, V. Deckert, 1994, British journal of pharmacology.

Naloxone effect on the neurological deficit induced by forebrain ischemia in rats.

M. Plotkine, D. Pruneau, R. Boulu, 1986, Life sciences.

Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs

D. Pruneau, J. Paquet, J. Luccarini, 1996, British journal of pharmacology.

Properties of [3H]LF 7-0156, a new nonpeptide antagonist radioligand for the type 1 angiotensin II receptor.

J. Marie, J. Bonnafous, D. Pruneau, 1994, Molecular pharmacology.

Model of global forebrain ischemia in the unanesthetized rat.

M. Plotkine, D. Pruneau, R. Boulu, 1986, Journal de pharmacologie.

Modeling the Electro-chemical Properties of Microbial Opsin ChrimsonR for Application to Optogenetics-based Vision Restoration

Ryad Benosman, Quentin Sabatier, Joël Chavas, 2018, bioRxiv.